Reviewing BeOne Medicines (NASDAQ:ONC) & Veru (NASDAQ:VERU)

BeOne Medicines (NASDAQ:ONC) and Veru (NASDAQ:VERU) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for BeOne Medicines and Veru, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0	1	16	1	3.00
Veru	1	0	3	0	2.50

BeOne Medicines presently has a consensus target price of $436.92, suggesting a potential upside of 5.04%. Veru has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Given Veru’s higher possible upside, analysts clearly believe Veru is more favorable than BeOne Medicines.

Earnings and Valuation

This table compares BeOne Medicines and Veru”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$6.61 billion	6.91	$286.93 million	$7.87	52.85
Veru	N/A	N/A	-$22.73 million	($0.69)	-3.07

BeOne Medicines has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BeOne Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.2, meaning that its stock price is 220% less volatile than the S&P 500.

Profitability

This table compares BeOne Medicines and Veru’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	13.86%	19.04%	10.70%
Veru	N/A	-47.58%	-35.83%

Insider and Institutional Ownership

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats Veru on 12 of the 14 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

About Veru

Veru Inc. is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function. Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.